- Home
- DRCT vs SNSE Comparison
DRCT vs SNSE Comparison
Compare DRCT & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRCT
- SNSE
- Stock Information
- Founded
- DRCT 2018
- SNSE 2005
- Country
- DRCT United States
- SNSE United States
- Employees
- DRCT N/A
- SNSE N/A
- Industry
- DRCT Computer Software: Programming Data Processing
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- DRCT Technology
- SNSE Health Care
- Exchange
- DRCT Nasdaq
- SNSE Nasdaq
- Market Cap
- DRCT 11.4M
- SNSE 10.8M
- IPO Year
- DRCT 2022
- SNSE 2021
- Fundamental
- Price
- DRCT $0.60
- SNSE $8.24
- Analyst Decision
- DRCT Strong Buy
- SNSE Strong Buy
- Analyst Count
- DRCT 1
- SNSE 4
- Target Price
- DRCT $6.00
- SNSE $72.50
- AVG Volume (30 Days)
- DRCT 580.2K
- SNSE 25.9K
- Earning Date
- DRCT 08-05-2025
- SNSE 08-05-2025
- Dividend Yield
- DRCT N/A
- SNSE N/A
- EPS Growth
- DRCT N/A
- SNSE N/A
- EPS
- DRCT N/A
- SNSE N/A
- Revenue
- DRCT $48,170,000.00
- SNSE N/A
- Revenue This Year
- DRCT $50.71
- SNSE N/A
- Revenue Next Year
- DRCT $26.31
- SNSE N/A
- P/E Ratio
- DRCT N/A
- SNSE N/A
- Revenue Growth
- DRCT N/A
- SNSE N/A
- 52 Week Low
- DRCT $0.44
- SNSE $5.00
- 52 Week High
- DRCT $6.59
- SNSE $17.40
- Technical
- Relative Strength Index (RSI)
- DRCT 58.19
- SNSE 52.43
- Support Level
- DRCT $0.50
- SNSE $6.33
- Resistance Level
- DRCT $0.79
- SNSE $10.99
- Average True Range (ATR)
- DRCT 0.06
- SNSE 1.00
- MACD
- DRCT 0.00
- SNSE 0.12
- Stochastic Oscillator
- DRCT 33.57
- SNSE 41.04
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).